School of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.
Neuropharmacology. 2010 Mar-Apr;58(4-5):722-9. doi: 10.1016/j.neuropharm.2009.12.020. Epub 2010 Jan 5.
This study aimed to examine the feasibility of using thyroid hormone (TH) as a therapeutic agent for Alzheimer's disease (AD). Mice were injected intra-hippocampally aggregated amyloid beta-peptide (Abeta) to produce AD animal model. Intraperitoneal administration of l-thyroxine (L-T4) into Abeta-induced AD model mice prevented their cognitive impairment and improved their memory function. The mechanisms of L-T4 treating AD might be associated with regulating cholinergic function, protecting the brains of AD model mice against damage from free radicals, and rescuing hippocampal neurons from apoptosis. The results of the present study indicate that the use of TH has some therapeutic potential in AD.
本研究旨在探讨甲状腺激素 (TH) 作为治疗阿尔茨海默病 (AD) 的药物的可行性。通过向海马内注射聚集的淀粉样β肽 (Abeta) 来制备 AD 动物模型。向 Abeta 诱导的 AD 模型小鼠腹腔内给予左旋甲状腺素 (L-T4)，可预防其认知障碍并改善其记忆功能。L-T4 治疗 AD 的机制可能与调节胆碱能功能、保护 AD 模型小鼠的大脑免受自由基损伤以及挽救海马神经元免于凋亡有关。本研究结果表明，TH 的使用在 AD 中具有一定的治疗潜力。
